Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Coherus BioSciences (CHRS Quick QuoteCHRS - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.

Coherus BioSciences is one of 905 companies in the Medical group. The Medical group currently sits at #3 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.

The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. CHRS is currently sporting a Zacks Rank of #1 (Strong Buy).

The Zacks Consensus Estimate for CHRS's full-year earnings has moved 33.33% higher within the past quarter. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.

Based on the most recent data, CHRS has returned 5.47% so far this year. At the same time, Medical stocks have gained an average of 2.61%. This means that Coherus BioSciences is performing better than its sector in terms of year-to-date returns.

Looking more specifically, CHRS belongs to the Medical - Biomedical and Genetics industry, a group that includes 387 individual stocks and currently sits at #83 in the Zacks Industry Rank. On average, this group has gained an average of 0.47% so far this year, meaning that CHRS is performing better in terms of year-to-date returns.

Investors in the Medical sector will want to keep a close eye on CHRS as it attempts to continue its solid performance.